CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2016 and corporate highlights.
“During the first quarter, Catabasis made substantial progress with edasalonexent, formerly known as CAT-1004, and CAT-2054, our two programs in the clinic,” said Jill C. Milne, Chief Executive Officer of Catabasis.
“During the first quarter, Catabasis made substantial progress with edasalonexent, formerly known as CAT-1004, and CAT-2054, our two programs in the clinic,” said Jill C. Milne, Chief Executive Officer of Catabasis.
